Literature DB >> 8576553

MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis. Part 2: MRI findings in 21 patients.

S L Vanhanen1, R Raininko, T Autti, P Santavuori.   

Abstract

The purpose of this study was to demonstrate the course of infantile neuronal ceroid-lipofuscinosis with brain magnetic resonance imaging (MRI) in children aged 3 months to 11 years. Twenty-one patients and 46 neurologically normal controls of the same age were examined. The images were evaluated visually; then signal intensities were measured and related to those of references. MRI abnormalities were detectable before clinical symptoms. The radiologic picture of the brain varied with the duration of the disease. Pathognomonic MRI findings in the early stage of the disease were generalized cerebral atrophy, strong thalamic hypointensity to the white matter and to the basal ganglia, and thin periventricular high-signal rims from 13 months onward on T2-weighted images. In patients over 4 years old, cerebral atrophy was extreme, and the signal intensity of the entire white matter was higher than that of the gray matter, which is the reverse of normal. This study showed that the abnormalities seen on MRI progress rapidly during the first 4 years of life, then stabilize, in conformity with the clinical and histopathologic pictures of infantile neuronal ceroid-lipofuscinosis.

Entities:  

Mesh:

Year:  1995        PMID: 8576553     DOI: 10.1177/088307389501000604

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  14 in total

Review 1.  Neuronal ceroid lipofuscinoses: a review.

Authors:  N Nardocci; F Cardona
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 2.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

3.  Neuronal ceroid lipofuscinosis: genetic and phenotypic spectrum of 14 patients from Turkey.

Authors:  Melis Kose; Engin Kose; Aycan Ünalp; Ünsal Yılmaz; Selvinaz Edizer; Hande Gazeteci Tekin; Pakize Karaoğlu; Taha Reşid Özdemir; Esra Er; Hüseyin Onay; Eser Sozmen Yildirim
Journal:  Neurol Sci       Date:  2021-01-23       Impact factor: 3.307

4.  MRI Brain Volume Measurements in Infantile Neuronal Ceroid Lipofuscinosis.

Authors:  E H Baker; S W Levin; Z Zhang; A B Mukherjee
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-20       Impact factor: 3.825

Review 5.  Decreased T2 signal in the thalami may be a sign of lysosomal storage disease.

Authors:  Taina Autti; Raimo Joensuu; Laura Aberg
Journal:  Neuroradiology       Date:  2007-03-03       Impact factor: 2.804

Review 6.  Clinical aspects of neuropathic lysosomal storage disorders.

Authors:  Laura Bannach Jardim; Maria Mercedes Villanueva; Carolina F Moura de Souza; Cristina B Oliveira Netto
Journal:  J Inherit Metab Dis       Date:  2010-05-21       Impact factor: 4.982

7.  Invited article: an MRI-based approach to the diagnosis of white matter disorders.

Authors:  Raphael Schiffmann; Marjo S van der Knaap
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

8.  Subdural fluid collections in patients with infantile neuronal ceroid lipofuscinosis.

Authors:  Sondra W Levin; Eva H Baker; Andrea Gropman; Zenaide Quezado; Ning Miao; Zhongjian Zhang; Alice Jollands; Matteo Di Capua; Rafael Caruso; Anil B Mukherjee
Journal:  Arch Neurol       Date:  2009-12

9.  Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.

Authors:  Sondra W Levin; Eva H Baker; Wadih M Zein; Zhongjian Zhang; Zenaide M N Quezado; Ning Miao; Andrea Gropman; Kurt J Griffin; Simona Bianconi; Goutam Chandra; Omar I Khan; Rafael C Caruso; Aiyi Liu; Anil B Mukherjee
Journal:  Lancet Neurol       Date:  2014-07-02       Impact factor: 44.182

10.  Expanding the Neuroimaging Phenotype of Neuronal Ceroid Lipofuscinoses.

Authors:  A Biswas; P Krishnan; A Amirabadi; S Blaser; S Mercimek-Andrews; M Shroff
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.